Erratum: Novel permissive murine immunocompetent orthotopic colon carcinoma model for comparison of the antitumoral and safety profiles of three Adv-TKs

Correction to: Gene Therapy (2014) 21, 975–983; doi:10.1038/gt.2014.79; published online 4 September 2014

Since the publication of this article the authors have noticed an error with regard to Figures 2e and g. The correct Figure 2 is reproduced here.

Figure 2

Effects of Adv-TK, M7 and M8 on CMT-93 cells and non-cancerous cells in vitro. (a) CMT-93 cells were administered with increasing concentrations of GCV (0–600 μg ml⁻¹). Cell proliferation was assessed by MTT assay after 72 h. (b) CMT-93 cells were infected with various viral mutants at various MOI in the presence of 100 μg ml⁻¹ of GCV. Cell proliferation was assessed by MTT assay 72 h after infection. (c–d) Non-cancer cells, HUVEC and MCF-10A, were infected with various viral mutants at a MOI of 50 or 500 in the presence of 100 μg ml⁻¹ of GCV; transfect efficacy was determined 24 h after transfection of 500 MOI Adv-GFP, and cell proliferation was assessed by MTT assay 72 h after infection. (e) CMT-93 cells were infected with various viral mutants at a MOI of 2 or 50 in the presence of 100 μg ml⁻¹of GCV, apoptosis was assessed by flow cytometry 72 h after infection. (f) Non-cancer cells, HUVEC and MCF-10A, were infected with various viral mutants at a MOI of 50, apoptosis was assessed by flow cytometry 72 h after infection. (g) Representative flow cytometric analysis of the effects of Adv-TK, M7 and M8 administered in combination with 100 μg ml⁻¹ GCV in CMT-93 and MCF-10A cells. All the results were presented as the means of values obtained in three independent experiments.

The authors apologize for any inconvenience caused.